Compare Estee Lauder Companies Inc (EL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs ResMed Inc. — how do they compare? Estee Lauder Companies Inc trades at $97.24 (market cap $34.17B), while ResMed Inc. trades at $229.66 (market cap $31.89B). The key difference: Estee Lauder Companies Inc and ResMed Inc. are close in size by market cap, and Estee Lauder Companies Inc pays the higher dividend (1.48%). Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and ResMed Inc. for 51 Days on average.
| EL | RMD | |
|---|---|---|
Market Cap | $34.17B | $31.89B |
Volume | 3,921,497 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $277.88 |
52-Week Low | $67.23 | $182.82 |
Typical Hold Time | 122 Days | 51 Days |
Enterprise Value | $39.92B | $31.24B |
Dividend Yield | 1.48% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $94.45, up 1.17% with a bullish technical signal from moving averages. The company shows improving earnings momentum with three consecutive quarterly beats, though 2025 results showed a net loss of $1.13B on $14.33B revenue. Analyst consensus is mixed with 48% buy ratings and a $103 price target, while recent news highlights AI partnerships and leadership changes driving strategic repositioning.
The stock presents a turnaround opportunity with strong brand positioning and digital initiatives, but faces execution risks from recent profitability challenges and high debt levels. Near-term catalysts include Q3 earnings and continued margin recovery, though competitive pressures and macroeconomic sensitivity remain headwinds for the luxury beauty sector.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
